Abstract: Compounds of formula (I) and salts are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Abstract: Compounds of formula (I), salts and solvates are provided: Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Abstract: Compounds of formula (I) and salts and solvates are provided: wherein Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Abstract: Compounds of formula (I), salts and solvates are provided, Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Abstract: Compounds of formula (I) and salts thereof are provided: wherein R4, R5, R6, Q, A, and Y are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Abstract: Compounds of formula (I) and salts thereof are provided: wherein the groups are as defined in the specification. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.

Abstract: Compounds of formula (I), salts and solvates are provided: Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Abstract: Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Abstract: Compounds of formula (I) and salts and solvates are provided: wherein Uses of the compounds for the treatment of psychotic disorders and cognitive mpairment, are also disclosed.

Abstract: Compounds of formula (I) and salts are provided: wherein R6 is selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Abstract: Compounds of formula (I) and salts are provided: wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Abstract: Compounds of formula (I) and salts are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

Abstract: A method for producing trimethylene carbonate poly(trimethylene carbonate which comprises (a) introducing liquid poly(trimethylene carbonate) and an optional catalyst into a wiped film evaporator reactor under a vacuum about 15 kPa or less, said reactor having walls heated to at least about 230° C. and an internal condenser heated to a temperature above the boiling point of trimethylene carbonate, (b) spreading the poly(trimethylene carbonate) into a thin film and allowing it to flow down the interior surface of the heated walls, (c) depolymerizing the poly(trimethylene carbonate) to form trimethylene carbonate which is driven to the internal condenser and residue poly(trimethylene carbonate) which continues down the reactor, and (d) collecting the trimethylene carbonate in a cooled distillate receiver.

Abstract: A system and method for allowing a marketing entity or client to deliver marketing information on a product or service to a target group of consumers. The marketing entity can generate or modify parameters defining at least a part of a consumer interface and these can be associated with consumer data so that a user interface is associated with a target group of consumers. The target group of consumers can then be notified of the existence of the interface. This can be facilitated either by the automatic generation of the notification e.g. by e-mail, fax, or SMS message, or by the generation of contact information for the consumers to allow manual notification e.g. mail, telephone call or fax. The consumers are then able to access the interface and gain access to the information on a product or service. The consumer interface can comprise static information, which is dynamically generated on a request from a consumer and can comprise dynamic information, such as multimedia data.

Abstract: Methods are disclosed for assessing the toxic or pathologic effects of a selected environmental stimulus or reagent on a mammalian cell by determining on a DNA grid a “fingerprint” hybridization pattern. The fingerprint pattern is characteristic of chemically or structurally diverse stimuli or reagents, which having a common adverse effect on gene transcription. A test compound is screened for a similar toxic effect by comparing its hybridization pattern on a similar grid to the fingerprint.

Abstract: A method for analyzing the protein or peptide content of a mixture comprising exposing a spatial array of protein recognition units to the protein or peptide containing mixture, and detecting the binding of proteins or peptides to the protein recognition units.

Abstract: A selection diversity system and method for use in a TDMA (time division multiple access) radio system, particularly suited for DECT (Digital Enhanced Cordless Telephone) or PWT (personal wireless telephony) applications. A digitized version of a received signal is buffered long enough to allow selection diversity measurements to occur without corrupting the demodulation of the desired signal. While the received signal is being buffered, a single receiver makes a performance measurement on each of two antennas in sequence during the beginning of a received data burst, the beginning of the burst being determined by a timing signal fed back from a previous burst. The previously unused antenna is measured first to minimize the likelihood of having to perform two antenna switches. Also while the received signal is buffered, timing recovery and frequency offset correction are performed.